WO2022243510A1 - Combinations for use in brain health and increasing motivation - Google Patents
Combinations for use in brain health and increasing motivation Download PDFInfo
- Publication number
- WO2022243510A1 WO2022243510A1 PCT/EP2022/063711 EP2022063711W WO2022243510A1 WO 2022243510 A1 WO2022243510 A1 WO 2022243510A1 EP 2022063711 W EP2022063711 W EP 2022063711W WO 2022243510 A1 WO2022243510 A1 WO 2022243510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- vitamin
- glutathione
- composition according
- performance
- Prior art date
Links
- 230000001965 increasing effect Effects 0.000 title claims abstract description 21
- 230000008450 motivation Effects 0.000 title claims description 8
- 230000036995 brain health Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 96
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 23
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims abstract description 20
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 14
- 235000021119 whey protein Nutrition 0.000 claims abstract description 14
- 239000004471 Glycine Substances 0.000 claims abstract description 13
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 13
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 12
- 230000003340 mental effect Effects 0.000 claims abstract description 12
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 11
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 11
- 239000011720 vitamin B Substances 0.000 claims abstract description 11
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims abstract description 10
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960005559 sulforaphane Drugs 0.000 claims abstract description 10
- 235000015487 sulforaphane Nutrition 0.000 claims abstract description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 143
- 229960003180 glutathione Drugs 0.000 claims description 66
- 108010024636 Glutathione Proteins 0.000 claims description 48
- 235000003969 glutathione Nutrition 0.000 claims description 46
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 38
- 210000004556 brain Anatomy 0.000 claims description 26
- 229940011671 vitamin b6 Drugs 0.000 claims description 19
- 235000015872 dietary supplement Nutrition 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 229930003779 Vitamin B12 Natural products 0.000 claims description 12
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 12
- 235000019163 vitamin B12 Nutrition 0.000 claims description 12
- 239000011715 vitamin B12 Substances 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 11
- 235000008160 pyridoxine Nutrition 0.000 claims description 8
- 239000011677 pyridoxine Substances 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000013353 coffee beverage Nutrition 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000008447 perception Effects 0.000 claims description 4
- 229930003761 Vitamin B9 Natural products 0.000 claims description 2
- 230000003931 cognitive performance Effects 0.000 claims description 2
- 235000019159 vitamin B9 Nutrition 0.000 claims description 2
- 239000011727 vitamin B9 Substances 0.000 claims description 2
- 235000008453 RTD coffee Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 27
- 235000013305 food Nutrition 0.000 description 19
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 17
- 230000003834 intracellular effect Effects 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 11
- 235000019158 vitamin B6 Nutrition 0.000 description 11
- 239000011726 vitamin B6 Substances 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 10
- 210000001009 nucleus accumben Anatomy 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- 239000007938 effervescent tablet Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 6
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 6
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000036992 cognitive tasks Effects 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- -1 L-Glutathion Chemical compound 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000008151 pyridoxamine Nutrition 0.000 description 4
- 239000011699 pyridoxamine Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical class OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- 229960003581 pyridoxal Drugs 0.000 description 3
- 235000008164 pyridoxal Nutrition 0.000 description 3
- 239000011674 pyridoxal Substances 0.000 description 3
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 3
- 235000008974 pyridoxamine 5'-phosphate Nutrition 0.000 description 3
- 239000011580 pyridoxamine 5'-phosphate Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QFVJNEASAAJIDF-ZETCQYMHSA-N (2s)-2-cyclopropyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C1CC1 QFVJNEASAAJIDF-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000234282 Allium Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 2
- 108010036164 Glutathione synthase Proteins 0.000 description 2
- 102100034294 Glutathione synthetase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 102100034407 Pyridoxine-5'-phosphate oxidase Human genes 0.000 description 2
- 101710168781 Pyridoxine-5'-phosphate oxidase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000004727 amygdala Anatomy 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000008202 granule composition Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000010282 redox signaling Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XPFJZGJBRMTXCE-SNVBAGLBSA-N (2r)-2-(2-chlorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)C1=CC=CC=C1Cl XPFJZGJBRMTXCE-SNVBAGLBSA-N 0.000 description 1
- IEQBOUSLFRLKKX-SNVBAGLBSA-N (2r)-2-(4-fluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)C1=CC=C(F)C=C1 IEQBOUSLFRLKKX-SNVBAGLBSA-N 0.000 description 1
- VJYLMXXKPBZDHN-MRVPVSSYSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-thiophen-3-ylacetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)C=1C=CSC=1 VJYLMXXKPBZDHN-MRVPVSSYSA-N 0.000 description 1
- AMKHAJIFPHJYMH-SSDOTTSWSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-4-ynoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC#C AMKHAJIFPHJYMH-SSDOTTSWSA-N 0.000 description 1
- WAMWSIDTKSNDCU-SSDOTTSWSA-N (2r)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@H](N)C1CCCCC1 WAMWSIDTKSNDCU-SSDOTTSWSA-N 0.000 description 1
- WNNNWFKQCKFSDK-SCSAIBSYSA-N (2r)-2-azaniumylpent-4-enoate Chemical compound [O-]C(=O)[C@H]([NH3+])CC=C WNNNWFKQCKFSDK-SCSAIBSYSA-N 0.000 description 1
- DGYHPLMPMRKMPD-SCSAIBSYSA-N (2r)-2-azaniumylpent-4-ynoate Chemical compound OC(=O)[C@H](N)CC#C DGYHPLMPMRKMPD-SCSAIBSYSA-N 0.000 description 1
- QSUXZIPXYDQFCX-SNVBAGLBSA-N (2r)-2-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)C1CCCCC1 QSUXZIPXYDQFCX-SNVBAGLBSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- VJYLMXXKPBZDHN-QMMMGPOBSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-thiophen-3-ylacetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C=1C=CSC=1 VJYLMXXKPBZDHN-QMMMGPOBSA-N 0.000 description 1
- WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1
- QSUXZIPXYDQFCX-JTQLQIEISA-N (2s)-2-cyclohexyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C1CCCCC1 QSUXZIPXYDQFCX-JTQLQIEISA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HSTNUHGEHQNAEP-UHFFFAOYSA-N 2-(2-fluoro-n-methylsulfonylanilino)acetic acid Chemical compound OC(=O)CN(S(=O)(=O)C)C1=CC=CC=C1F HSTNUHGEHQNAEP-UHFFFAOYSA-N 0.000 description 1
- QXTAWUQQXRUPAP-UHFFFAOYSA-N 2-(4-fluoro-n-methylsulfonylanilino)acetic acid Chemical compound OC(=O)CN(S(=O)(=O)C)C1=CC=C(F)C=C1 QXTAWUQQXRUPAP-UHFFFAOYSA-N 0.000 description 1
- UIDQSTVPYKMCEY-UHFFFAOYSA-N 2-[(2,4-dimethoxyphenyl)methyl-(9h-fluoren-9-ylmethoxycarbonyl)amino]acetic acid Chemical compound COC1=CC(OC)=CC=C1CN(CC(O)=O)C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UIDQSTVPYKMCEY-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 244000221633 Brassica rapa subsp chinensis Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 description 1
- 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 description 1
- RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- KSPQDMRTZZYQLM-UHFFFAOYSA-N N-(2-furoyl)glycine Chemical compound OC(=O)CNC(=O)C1=CC=CO1 KSPQDMRTZZYQLM-UHFFFAOYSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 108010070648 Pyridoxal Kinase Proteins 0.000 description 1
- 102100038517 Pyridoxal kinase Human genes 0.000 description 1
- 108030000988 Pyridoxamine-phosphate transaminases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FVRWSIPJNWXCEO-YUMQZZPRSA-N S-acetylglutathione Chemical compound OC(=O)CNC(=O)[C@H](CSC(=O)C)NC(=O)CC[C@H](N)C(O)=O FVRWSIPJNWXCEO-YUMQZZPRSA-N 0.000 description 1
- 108700017742 S-acetylglutathione Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 229940010007 cobalamins Drugs 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VMCGMPITVQIMGK-ZLTKDMPESA-N dicyclohexylazanium;(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-4-enoate Chemical compound C1CCCCC1NC1CCCCC1.CC(C)(C)OC(=O)N[C@H](C(O)=O)CC=C VMCGMPITVQIMGK-ZLTKDMPESA-N 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- SYKQOFCBFHMCJV-UHFFFAOYSA-N ethyl 2-cyano-3-phenylpropanoate Chemical compound CCOC(=O)C(C#N)CC1=CC=CC=C1 SYKQOFCBFHMCJV-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- XZAPFOKZCXRSDH-UHFFFAOYSA-N methyl 2-[bis(methylsulfanyl)methylideneamino]acetate Chemical compound COC(=O)CN=C(SC)SC XZAPFOKZCXRSDH-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical compound COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003122 modulative effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000031868 operant conditioning Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- WHOMFKWHIQZTHY-UHFFFAOYSA-L pyridoxine 5'-phosphate(2-) Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-L 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 1
- 229960004986 pyritinol Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 1
- 235000021467 vitamin B7(Biotin) Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
Definitions
- the present invention relates to compositions comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L-theanine or their functional derivatives and at least one B vitamins for increasing motivational performance and/or mental energy.
- the present invention further relates to such compositions provided as a kit together with a digital tool such as a companion App.
- Glutathione is an essential antioxidant used by the body to prevent cellular and tissue damage. It is involved in many fundamental metabolic processes ranging from the nitric oxide cycle to dietary mineral incorporation. Additionally, glutathione is instrumental for cells to regulate their division and their differentiation from progenitor cells into mature somatic cells.
- glutathione binds circulating reactive oxygen species (ROS) which can cause cellular and DNA damage if left unchecked.
- ROS reactive oxygen species
- Reactive oxygen species also known as free radicals, are byproducts of metabolism and can be broadly harmful to the body.
- glutathione binds to ROS thereby becoming oxidized. This means that glutathione prevents important cellular proteins or DNA from being oxidized, which can inhibit their function.
- High concentrations of oxidized glutathione in the brain are a hallmark that the brain is in a compromised state, but high concentrations in the blood plasma may be considered to be healthy and normal. The reason is that oxidized glutathione must return to the bloodstream from the brain in order to discharge the ROS it carries into a metabolic processes which can make use of them constructively.
- the oxidized form of GSH can be locally reverted back into the reduced state by glutathione reductase or it can return from the brain to the bloodstream in order to discharge the ROS constructively.
- high concentrations of oxidized glutathione in the brain may mean that there is not enough glutathione to remove all of the reactive oxygen species that are circulating, indicating severe levels of stress.
- glutathione levels in blood plasma By only measuring glutathione levels in blood plasma, one may erroneously assume that circulating glutathione is normal, even in cognitively impaired individuals. Only recently, it was recognized that cognitively impaired individuals have decreased glutathione levels in the brain, however, it is not known under what conditions glutathione levels in the brain may transiently change in normal healthy individuals related to their performance of different cognitive and motor tasks.
- the present invention provides compositions and methods for enhancement of glutathione levels in the brain.
- the present invention provides compositions comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L- theanine or their functional derivatives and at least one B-vitamin.
- the present composition is for use in increasing glutathione levels in the brain and/or increasing motivational performance or mental energy in an individual.
- the present invention provides solutions for enhancement of glutathione in the brain, particularly in the nucleus accumbens region, during high energy demands in the brain.
- the composition is in the form of a food supplement or dietary supplement, such as a gummy, powder sachet or tablet.
- Vitamins are B Vitamins, such as B6, B9, B12.
- the present invention relates to a kit comprising a composition as described above and a digital tool.
- the digital tool is a companion App.
- the composition and the companion App helps the individual to achieve objectives and/or to support his motivation or focus; reduces his perception of effort to reach his objectives.
- FIGURES Figure 1 - Sulfurophane and Intracellular GSH Sulfurophane increases intracellular glutathione.
- Figure 2 Taurine and Intracellular GSH Taurine increases intracellular GSH.
- the “subject” or “individual” of the present invention is a human adult subject, preferably a healthy adult with the need to improve motivational performance through modulating glutathione levels in the brain.
- the compositions of the invention may be beneficially used for increasing glutathione level in the brain, in particular, the nucleus accumbens for preventing or treating conditions or diseases which are characterized by low glutathione levels in the brain, whether transient or chronic.
- stress refers to the consequence of the failure of a human or other animal to respond appropriately to physiological, emotional, or physical threats, whether actual or imagined.
- the psychobiological features of stress may present as manifestations of oxidative stress, i.e., an imbalance between the production and manifestation of reactive oxygen species and the ability of a biological system readily to detoxify the reactive intermediates or to repair the resulting damage.
- Disturbances in the normal redox state of tissues can cause toxic effects through the production of peroxides and free radicals that damage all of the components of the cell, including proteins, lipids, and DNA.
- Some reactive oxidative species can even act as messengers through a phenomenon called "redox signaling.”
- Reactive oxygen species play important roles in cell signaling, a process termed redox signaling. Thus, to maintain proper cellular homeostasis a balance must be struck between reactive oxygen production and consumption.
- One source of reactive oxygen under normal conditions in humans is the leakage of activated oxygen from mitochondria during oxidative phosphorylation.
- Other enzymes capable of producing superoxide (02-) are xanthine oxidase, NADPH oxidases and cytochromes P450. Hydrogen peroxide, another strong oxidizing agent, is produced by a wide variety of enzymes including several oxidases.
- treatment and “treating” include any effect that results in the improvement of the condition or disorder, for example lessening, reducing, modulating, or eliminating the condition or disorder.
- the term does not necessarily imply that a subject is treated until total recovery.
- Non-limiting examples of “treating” or “treatment of’ a condition or disorder include: (1) inhibiting the condition or disorder, i.e., arresting the development of the condition or disorder or its clinical symptoms and (2) relieving the condition or disorder, i.e., causing the temporary or permanent regression of the condition or disorder or its clinical symptoms.
- a treatment can be patient- or doctor-related.
- prevention or “preventing” mean causing the clinical symptoms of the referenced condition or disorder to not develop in an individual that may be exposed or predisposed to the condition or disorder but does not yet experience or display symptoms of the condition or disorder.
- condition and “disorder” mean any disease, condition, symptom, or indication.
- the relative terms “improved,” “increased,” “enhanced” and the like refer to the effects of the composition on increasing glutathione in the brain, in particular in the nucleus accumbens region of the brain, and subsequently improving the cognitive or motor performance in the individual subject.
- “Motivational performance” is synonymous with the terms “mental energy” and related terms of “volition”, “will-power”, “time-on-task”, “persistence”, “focus”, “self-control”, “sustained effort”, “vigor” and “self-efficacy”. All these terms relate to a person’s drive to initiate and do things. Motivational performance is linked to subjectively perceived self-efficacy and well-being.
- Motivational performance describes the subjective perception of mental resources available, which in turn is linked to cognitive functioning (Egan et al. (2015) Personality & Social Psychology Bulletin, 41(3), 336-350). For example, motivational performance is reduced in states of depression and anxiety (O’Connor et al. (2006) Nutrition Reviews, 64(7 Pt 2), S2-6). Measurement of “motivational performance” can be by both motor tasks and cognitive tasks. Typically, these motor tasks and cognitive tasks are performed under incentivized conditions, meaning that individuals get an incentive depending on their performance of the task.
- a motor task under incentivized conditions may be measured as an individual’s ability to perform a strenuous motor task, e.g. squeezing a handgrip measuring both force and endurance wherein the performance is normalised for individual muscular strength (Zhu et al. (2019) Neuroimage. Clinical, 23, 101922).
- a cognitive task under incentivized conditions may be an individual’s ability to perform a strenuous cognitive task, e.g. continuous/sustained attention and working memory (e.g. Unsworth et al. (2019) Journal of Experimental Psychology. Learning, Memory, and Cognition), mental arithmetic, or spatial reasoning (e.g. Nagase et al. (2015) Journal of the Society for Neuroscience, 38(10), 2631-2651) wherein the performance is normalised for individual capacity to perform this task.
- a strenuous cognitive task e.g. continuous/sustained attention and working memory (e.g. Unsworth et al. (2019) Journal of Experimental Psychology. Learning, Memory, and Cognition), mental arithmetic, or spatial reasoning (e.g. Nagase et al. (2015) Journal of the Society for Neuroscience, 38(10), 2631-2651) wherein the performance is normalised for individual capacity to perform this task.
- nucleus accumbens is the most ventral part of the striatum and is mainly connected to the limbic system. As a functionally central structure between amygdala, basal ganglia, mesolimbic dopaminergic regions, mediodorsal thalamus and prefrontal cortex, the nucleus accumbens appears to play a modulative role in the flow of the information from the amygdaloid complex to these regions. Together with the prefrontal cortex and amygdala, nucleus accumbens consists a part of the cerebral circuit which regulates functions associated with effort or motivated performance. It is anatomically located in a unique way to serve emotional and behavioral components of feelings.
- composition mean a product or composition that is intended for ingestion by an individual such as a human and provides at least one nutrient to the individual.
- compositions of the present disclosure can comprise, consist of, or consist essentially of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in a diet.
- the composition can be any kind of composition that is suitable for human and/or animal consumption.
- the composition may be selected from the group consisting of: food compositions, dietary supplements, nutritional compositions, nutraceuticals, powdered nutritional products to be reconstituted in water or milk before consumption, food additives, medicaments, beverages and drinks, including coffee based products (coffee RTD, coffee capsules, etc..).
- the composition is an oral nutritional supplement (ONS), a complete nutritional formula, a pharmaceutical, a medical or a food product.
- the composition is administered to the individual as a beverage.
- the composition may be stored in a sachet as a powder and then suspended in a liquid such as water for use.
- complete nutrition contains sufficient types and levels of macronutrients (protein, fats and carbohydrates) and micronutrients to be sufficient to be a sole source of nutrition for the individual to which the composition is administered. Individuals can receive 100% of their nutritional requirements from such complete nutritional compositions.
- compositions of the invention encompass “enteral administration” in all forms, although of oral administration is preferred.
- Each of the compounds can be administered at the same time as the other compounds (i.e., as a single unit) or separated by a time interval (i.e., in separate units).
- “Functional derivatives” of compounds of the invention are derived from a similar compound by a chemical reaction. “Functional derivatives” can be formed from the same precursor compound and may be administered to increase glutathione levels in the brain.
- a “kit” means that the components of the kit are physically associated in or with one or more containers and considered a unit for manufacture, distribution, sale, or use.
- Containers include, but are not limited to, bags, boxes, cartons, bottles, packages of any type or design or material, over-wrap, shrink-wrap, affixed components (e.g., stapled, adhered, or the like), or combinations thereof.
- composition comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L-theanine or their functional derivatives and at least one B Vitamin.
- composition is for use in increasing glutathione levels in the brain and/or increasing motivational performance or mental energy and vigor in an individual.
- Such composition increases glutathione in the nucleus accumbens region of the brain to provide the benefits to the subject.
- the B Vitamins comprises at least one of pyridoxine and/or Vitamin B12.
- composition of the invention is administered orally.
- a composition is a food supplement or dietary supplement.
- a composition is in the form of a tablet, a gummy or a powder sachet, for example.
- a composition of the invention is in the form of an effervescent tablet.
- the composition is provided as a kit with a Digital tool, such as a companion App.
- composition of the invention is used by healthy individuals in need of i) increasing motivational performance and/or mental energy, ii) increasing cognitive performance, iii) increasing productivity.
- composition of the invention is used in decreasing performance anxiety and/or stress.
- Glutathione Glutathione is the most abundant intracellular component of overall antioxidant defenses.
- GSH Glutathione Glutathione
- GSH a tripeptide, is synthesized from precursor amino-acids: glycine, cysteine and glutamate in two steps catalyzed by glutamate cysteine ligase (GCL, also known as gamma-glutamylcysteine synthetase, EC 6.3.2.2) and gamma-L-glutamyl-L-cysteine:glycine ligase (also known as glutathione synthetase, EC 6.3.2.3), and GSH synthesis occurs de novo in cells.
- GCL glutamate cysteine ligase
- GCL glutamate cysteine ligase
- glycine ligase also known as glutathione synthetase, EC 6.3.2.3
- Glutathione is also known as Gamma-Glutamylcysteinylglycine, Gamma-L-Glutamyl-L- Cysteinylglycine, Gamma-L-Glutamyl-L-Cysteinylglycine, Glutathion, Glutation, L-Gamma- Glutamyl-L-Cysteinyl-Glycine, L-Gamma-Glutamyl-L-Cysteinyl-Glycine, L-Glutathion, L- Glutathione, GSH, N-(N-L-gamma-Glutamyl-L-cysteinyl)glycine. It is typically administered as S- acetyl glutathione or reduced L-glutathione.
- Glutathione-rich food include: cruciferous vegetables, for example, broccoli, cauliflower,
- Glutathione-rich herbs include: for example, milk thistle, flaxseed, guso seaweed. Compositions and methods of the invention can also be used in combination with dietary recommendations for a glutathione-rich food to complement the diet.
- compositions and methods of the invention would also include the recommendation to have sufficient sleep.
- Psychigenic stress is defined as a state of imminent or perceived threat to homeostasis, where the brain and body invoke various physiological responses to adapt. Glutathione levels in the brain may be affected by such stress.
- Glycine or functional derivative thereof is selected from the group consisting of L-glycine, L- glycine ethyl ester, D-Allylglycine; N-[Bis(methylthio)methylene]glycine methyl ester; Boc-allyl- Gly-OH (dicyclohexylammonium) salt; Boc-D-Chg-OH; Boc-Chg-OH; (R)-N-Boc-(2'- chlorophenyl)glycine; Boc-L-cyclopropylglycine; Boc-L-cyclopropylglycine; (R)-N-Boc-4- fluorophenylglycine; Boc-D-propargylglycine; Boc-(S)-3-thienylglycine; Boc-(R)-3-thienylglycine; D-a-Cyclohexylglycine; L-a-Cyclopropylglycine; N-(2-fluorophen
- the glycine or functional derivative thereof can be administered in an amount of about 0.1 - 100 milligram (mg) of glycine or functional derivative thereof per kilogram (kg) of body weight of the subject.
- the daily doses for a 60 kg subject can be 6 to 6,000 mg/day for glycine or a functional derivative thereof.
- Ergothioneine is also known as ergothionine, 1-carboxy-2-[2-mercaptoimidazole-4-(or 5)- yljethylj-trimethyl-ammonium hydroxide, 2-Mercaptohistidine Trimethylbetaine, or I- ergothioneine. It is an amino acid that is found mainly in mushrooms, but also in king crab, meat from animals that have grazed on grasses containing ergothioneine, and other foods.
- the daily dosing of ergothioneine or a functional derivative thereof may be administered at 2 to 25 mg/day.
- L-theanine is synthesized from glutamic acid and ethylamide and found in foods such as green tea. It is not an antioxidant itself but promotes glutathione.
- the daily dosing of l-theanine or a functional derivative thereof may be administered at 50 mg to 200 mg/day.
- Sulforaphane exists in food in its food-bound form known as Glucoraphanin, a glycoside (bound to a sugar) or sulforaphane that is commonly seen as a prodrug or storage form of Sulforaphane.
- the daily dose of sulforaphane or a functional derivative thereof may be administered at 7 to 57 mg/day.
- Whey proteins and whey protein isolates contain high amounts of amino acids such as glycine, cysteine and leucine, especially in isolates enriched for alpha-lac.
- the daily dose of whey protein is 0.8 to 2.5g/kg body weight of whey proteins per day.
- Taurine also known as 2-aminoethanesulfonic acid is an organic acid that occurs naturally in food, especially in shellfish (eg, scallops, mussels, clams) and in the dark meat of turkey and chicken, as well as in other meats and eggs.
- the daily doses for a 60 kg subject up to 3000 mg/day of taurine or a functional derivative thereof are provided.
- B vitamins are used in the composition.
- suitable B vitamins include Vitamin B1 (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements)and combinations thereof.
- Vitamin B1 thiamine
- Vitamin B2 riboflavin
- Vitamin B3 niacin or niacinamide
- Vitamin B5 pantothenic acid
- Vitamin B6 pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride
- Vitamin B7 biotin
- Vitamin B9 folic acid
- Vitamin B12 variant cobalamins; commonly cyanocobalamin in vitamin supplements
- Pyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods.
- vitamin B6 can include one or more of the following: pyridoxine (PN), pyridoxal 5'-phosphate (PLP), pyridoxine 5'-phosphate (P5P), pyridoxal (PL), pyridoxamine (PM), pyridoxamine 5'-phosphate (PMP), 4-pyridoxic acid, and pyritinol.
- PN pyridoxine
- PLA pyridoxal 5'-phosphate
- P5P pyridoxine 5'-phosphate
- PL pyridoxamine
- PM pyridoxamine 5'-phosphate
- 4-pyridoxic acid pyritinol.
- at least a portion of any vitamin B6 is PN.
- At least a portion of the vitamin B6 can be PLP.
- pyridoxal kinase Absorbed pyridoxamine is converted to PMP by pyridoxal kinase, which is further converted to PLP by pyridoxamine-phosphate transaminase or pyridoxine 5'-phosphate oxidase which also catalyzes the conversion of PNP to PLP.
- Pyridoxine 5'-phosphate oxidase is dependent on flavin mononucleotide (FMN) as a cofactor produced from riboflavin (vitamin B2).
- Vitamin B6 can be administered in an amount of vitamin B6 in a daily dosage of about 1.0-600 mg vitamin B6, for example about 1.0-200mg vitamin B6, for example about 1.0-25.0 mg vitamin B6, for example about 10-20mg of Vitamin B6 / day.
- a daily dose of the composition can provide 0.1 to 50 times the recommended daily requirement (RDA) of Vitamin B12 per day, more preferably 0.1 to 40 times the recommended daily requirement (RDA) of Vitamin B12
- Such dosages may preferably include a daily dose of about 10, 20, 30, or 40 times the RDA of the Vitamin B12 per day.
- the daily dose provides 10 to 40, more preferably 10 to 30 or even more preferably 10 to 25 times the RDA of the Vitamin B12 per day, most preferably about 12 to 21 times the RDA of the Vitamin B12 per day.
- Vitamin B12 is 2.4 micrograms daily for humans of age 14 years and older, so such individuals may be administered a daily dose of the composition that provides about 0.002 mg to about 0.4 mg of Vitamin B12 per day, preferably 0.02 to 0.07 mg of Vitamin B12 per day, more preferably 0.03 to 0.05 mg of Vitamin B12 per day.
- One or more other vitamins are used in the composition.
- suitable other vitamins include vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin K, folic acid and biotin), and combinations thereof.
- “Vitamin” includes such compounds obtained naturally from plant and animal foods or synthetically made, pro-vitamins, derivatives thereof, and analogs thereof.
- the compositions are food compositions, including human and pet food compositions.
- the food composition is a product with at least one nutrient for improving motivation performance or mental energy/ vigor.
- compositions may supply the necessary dietary requirements for an animal, animal treats (e.g., biscuits), or dietary supplements.
- the compositions may be a dry composition (e.g., kibble), semi-moist composition, wet composition, or any mixture thereof.
- the composition is a dietary supplement such as a gravy, drinking water, beverage, yogurt, powder, granule, paste, suspension, chew, morsel, treat, snack, pellet, pill, capsule, tablet, or any other suitable delivery form.
- the dietary supplement is to be administered to the animal in small amounts, or in the alternative, can be diluted before administration to an animal.
- the dietary supplement may require admixing or can be admixed with water or other diluent prior to administration to the animal.
- the composition is in the form of a food supplement or dietary supplement, in particular in the form of a tablet, a powder sachet or a gummy.
- the composition is in the form of an effervescent tablet.
- the effervescent tablets can be produced and controlled same as conventional tablets. These controls include physicochemical properties such as hardness, weight variation, friability, solution time, pH and content uniformity.
- the effervescent tablets can be produced by a direct compression method, a fusion method, a wet or dry granulation method, or any other suitable method. Low relative humidity (e.g., maximum of 25% or less) and moderate to cool temperatures (e.g., about 25 °C or 77 °F) in the environment may be essential to prevent sticking granule or tablets to the tablet press machine.
- the effervescent tablet can be formed by compressing the ingredients in the form of powders into a dense mass, for example, by a tablet press machine.
- the powdered ingredients may be first granulized to similar or equal sizes before being made into tablets, so that the mixtures of powder have excellent flowability without particles segregation. Granulating may not be required if the raw materials are selected to achieve a free- flowing, non-segregating, compressible powder blend.
- the tablets can then be dried by heat, such as in an oven with air circulation, at a suitable temperature for a suitable time and after cooling can be packed in a suitable package.
- the ingredients can be mixed in a suitable mixer, such as a blender, for an appropriate time. Then, the obtained mixture can be heated to a suitable temperature. The powder may be mixed regularly until the crystallization water of citric acid is released as binder factor (e.g., approximately 30 minutes) and an appropriate pasty mass is obtained. This wet mass can be passed through a sieve to obtain the desired granules, which can then be dried at a suitable temperature for an appropriate time. After drying, the granules can be passed through the sieve again. Other ingredients can be added to the granule mass and mixed for a suitable time. The granule mixtures then can be compressed into tablets by the tablet press machine. Finally, the tablets can be dried and packed in a suitable package.
- a suitable mixer such as a blender
- the ingredients may be milled by a miller, either separately or as a mixture with ethanol, ethanol-water mixture, isopropanol, etc., and the obtained powder can be passed through a sieve and then blended.
- a binder solution can be added to the mixture to form a pasty mass.
- This pasty mass can then be passed through a sieve to obtain desired granules, which can then dried.
- the dried mass can be passed through a sieve again, and other ingredients can be added and mixed.
- the obtained granule mixtures then can be compressed into tablets by the tablet press machine. Finally, the tablets can be dried and packed in a suitable package.
- wet granulation can also be performed by carefully adding 0.1 to 1.0 per cent water (weight-to-weight basis) to a blend of raw materials that possess the uniformity, compressibility, and flowability needed to produce good-quality tablets, but which lacks the needed binding properties.
- the free water which is usually added in the form of a fine spray to selected formulation components while mixing in a suitable blender acts as a binder.
- the granulation steps must be precisely timed and the ingredients mixed thoroughly to distribute the granulating fluid evenly in the blend.
- the mix is then quickly discharged to drying ovens. After drying, the granules are sized, and a final mix is performed. The granules are then compressed into tablets using tablet machines.
- the dry granulation method can use special processing equipment known as a “roller compactor” or “chilsonator.” These machines compress premixed powders between two counterrotating rollers under extreme pressure. Depending on the configuration of the roller, the feed material may be compacted into dense ribbon-like materials known as flakes (smooth rolls) or dense briquettes (almond or stick-shaped) if the rollers have grooved or etched surfaces.
- roll compactor or “chilsonator.” These machines compress premixed powders between two counterrotating rollers under extreme pressure.
- the feed material may be compacted into dense ribbon-like materials known as flakes (smooth rolls) or dense briquettes (almond or stick-shaped) if the rollers have grooved or etched surfaces.
- the compressed material is reduced to the proper size for tablet granulation purposes.
- Another dry granulation procedure is slugging, in which the powder particles are compressed into large flat tablets or pellets using a tablet press or more usually, a heavy-duty tablet-compacting equipment. The resulting tablet or slug are milled to yield the desired granule characteristics.
- the effervescent tablet can be made in any shape and can have any suitable size.
- the tablet can be 5 mm to 20 mm long, thick, and/or in diameter if having a round shape.
- the size of the tablet can be from 5 mm to 10 mm, 5 mm to 15 mm, 10 mm to 15 mm, 10 mm to 20 mm, or 15 mm to 20 mm.
- the effervescent tablet may comprise a binder, such as polyvinylpyrolidone (PVP) or any other suitable binder.
- the binder is preferably water-soluble. It can be added as dry powder or in a wet form as an aqueous or hydroalcoholic solution. Mannitol, PEG 6000 and water in small amounts can also be used as a binder. PEG 6000 at 3% use level can be used as a dry binder.
- the ideal amount of binder is one that makes the tablet hard enough to handle but soft enough to disintegrate and dry enough to be stable.
- the effervescent tablet may also be formulated without a binder. Beverage compositions
- the compositions are beverage compositions.
- Such beverage compositions are meant to be consumed by a human or animal.
- the beverage is a milk-based beverage; a performance nutrition product, a medical nutrition product; a milk product, e.g. a milk drink, a product with at least one nutrient for improving motivation performance (incl. focus) or mental energy (incl. vigor).
- the composition can be formulated as a “dairy product” together with milk proteins, e.g., milk protein concentrate or milk protein isolate; caseinates or casein, e.g., micellar casein concentrate or micellar casein isolate; or whey protein, e.g., whey protein concentrate or whey protein isolate.
- milk proteins e.g., milk protein concentrate or milk protein isolate
- caseinates or casein e.g., micellar casein concentrate or micellar casein isolate
- whey protein e.g., whey protein concentrate or whey protein isolate.
- at least a portion of the protein can be plant protein such as one or more of soy protein, pea protein or canola protein.
- the composition of the invention can be formulated as a “nutritional supplement” together with glutathione enhancing compounds of the invention.
- the compounds of the invention can be used alone or in combination with appropriate additives to make tablets, gummies, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose functional derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
- the composition of the invention can be administered at least one day per week, preferably at least two days per week, more preferably at least three or four days per week (e.g., every other day), most preferably at least five days per week, six days per week, or seven days per week.
- the time period of administration can be at least one week, preferably at least one month, more preferably at least two months, most preferably at least three months, for example at least four months.
- dosing is at least daily; for example, a subject may receive one or more doses daily.
- the administration continues for the remaining life of the individual.
- the administration occurs until no detectable symptoms of the condition remain.
- the administration occurs until a detectable improvement of at least one symptom occurs and, in further cases, continues to remain ameliorated.
- the ideal duration of the administration of the composition can be determined by those of skill in the art.
- composition is provided as a kit with a Companion App.
- the composition or kit helps the individual to achieve objectives and/or to support his motivation or focus; reduces his perception of effort to reach his objectives.
- objectives may include any global objectives or daily objectives related to pre-defined goals embodied within the app, such as lifestyle changes, including weight-loss, healthy eating, physical exercise or productivity at work or in private life, as well as any other user-defined goals.
- the companion app presents a onboarding questionnaire, displayed on first launch, to determine consumer wishes and concerns.
- the companion app tracks the progress towards the objectives, as well as activities (physical activity, sleep duration, etc..), optionally through digital tools (connected watch, etc).
- the companion app allows the user to indicate whether or not they have consumed the product.
- the companion app allows the user to capture their mood each day, and visualize the mood together with daily goals in a graph or timeline format.
- the companion app provides rewards in the form of digital trophies, kudo points, or discount vouchers.
- GSH-GloTM Assay is a luminescent-based assay for the detection and quantification of reduced and/or total glutathione levels in cells.
- the assay converted luciferin derivatives into luciferin in the presence of GSH.
- the reaction was catalyzed by a glutathione S-transferase (GST) enzyme supplied in the kit.
- GST glutathione S-transferase
- the luciferin formed was detected in a coupled reaction using Ultra-GloTM Recombinant Luciferase that generated a glow type luminescence that was proportional to the amount of glutathione present in cells.
- a standard curve was used for each biological replicate and at least 4 technical replicates were done for each condition and for each biological replicate. 10% of lysate of each technical and biological replicate was used to measure protein amount by BCA and used to normalize the GSH intracellular content to total proteins. Buthionine sulfoximine (BSO) a specific inhibitor of g-glutamylcysteine ligase (GCL) was added at 15mM at the time of the start of the treatment to confirm the specificity of the readout. Measurements were performed 48hrs after treatment. Results were compared to the control condition for each biological replicate and for each condition.
- BSO Buthionine sulfoximine
- GCL g-glutamylcysteine ligase
- Figure 1 demonstrates that Sulfurophane increases intracellular glutathione.
- Figure 2 demonstrates that Taurine increases intracellular glutathione.
- Figure 3 demonstrates that Ergothioneine increases intracellular glutathione.
- Figure 4 demonstrates that L-theanine increases intracellular glutathione.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to compositions comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L-theanine or their functional derivatives and at least one B vitamins for increasing motivational performance and/or mental energy. The present invention further relates to such compositions provided as a kit together with a digital tool such as a companion App.
Description
COMBINATIONS FOR USE IN BRAIN HEALTH AND INCREASING MOTIVATION
FIELD OF THE INVENTION
The present invention relates to compositions comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L-theanine or their functional derivatives and at least one B vitamins for increasing motivational performance and/or mental energy. The present invention further relates to such compositions provided as a kit together with a digital tool such as a companion App.
BACKGROUND TO THE INVENTION
Glutathione (GSH) is an essential antioxidant used by the body to prevent cellular and tissue damage. It is involved in many fundamental metabolic processes ranging from the nitric oxide cycle to dietary mineral incorporation. Additionally, glutathione is instrumental for cells to regulate their division and their differentiation from progenitor cells into mature somatic cells.
As one of the body’s core antioxidants, glutathione binds circulating reactive oxygen species (ROS) which can cause cellular and DNA damage if left unchecked. Reactive oxygen species, also known as free radicals, are byproducts of metabolism and can be broadly harmful to the body. To scavenge circulating ROS, glutathione binds to ROS thereby becoming oxidized. This means that glutathione prevents important cellular proteins or DNA from being oxidized, which can inhibit their function.
Increased oxidative damage and decreased glutathione levels are observed under situations of high energetic demand in the brain such as psychogenic stress.
High concentrations of oxidized glutathione in the brain are a hallmark that the brain is in a compromised state, but high concentrations in the blood plasma may be considered to be healthy and normal. The reason is that oxidized glutathione must return to the bloodstream from the brain in order to discharge the ROS it carries into a metabolic processes which can make use of them constructively. Alternatively, the oxidized form of GSH can be locally reverted back into the reduced state by glutathione reductase or it can return from the brain to the bloodstream in order to discharge the ROS constructively. As such, high concentrations of oxidized glutathione in the brain may mean that there is not enough glutathione to remove all of the reactive oxygen species that are circulating, indicating severe levels of stress.
By only measuring glutathione levels in blood plasma, one may erroneously assume that circulating glutathione is normal, even in cognitively impaired individuals. Only recently, it was recognized that cognitively impaired individuals have decreased glutathione levels in the brain, however, it is not known under what conditions glutathione levels in the brain may transiently change in normal healthy individuals related to their performance of different cognitive and motor tasks.
Direct supplementation with GSH is a challenging approach, particularly because it can be rapidly degraded in the liver into its constituent amino acids as well as be partially hydrolyzed and oxidized. Consequently, GSH bioavailability is limited following oral administration. Therefore, there is a need to find compositions and methods of increasing glutathione in the brain in situations of high energetic demand in the brain.
SUMMARY OF THE INVENTION
The present invention provides compositions and methods for enhancement of glutathione levels in the brain. In particular, the present invention provides compositions comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L- theanine or their functional derivatives and at least one B-vitamin. The present composition is for use in increasing glutathione levels in the brain and/or increasing motivational performance or mental energy in an individual.
As mentioned above, direct oral administration of glutathione has limited bioavailable effectiveness. The present invention provides solutions for enhancement of glutathione in the brain, particularly in the nucleus accumbens region, during high energy demands in the brain.
In a preferred embodiment, the composition is in the form of a food supplement or dietary supplement, such as a gummy, powder sachet or tablet.
In a preferred embodiment, Vitamins are B Vitamins, such as B6, B9, B12.
In another embodiment, the present invention relates to a kit comprising a composition as described above and a digital tool.
In a preferred embodiment, the digital tool is a companion App.
In another embodiment, the composition and the companion App helps the individual to achieve objectives and/or to support his motivation or focus; reduces his perception of effort to reach his objectives.
DESCRIPTION OF FIGURES Figure 1 - Sulfurophane and Intracellular GSH Sulfurophane increases intracellular glutathione. Figure 2 - Taurine and Intracellular GSH Taurine increases intracellular GSH.
Figure 3 - Ergothioneine and intracellular GSH Ergothionine increases intracellular GSH.
Figure 4 - L-Theanine and intracellular GSH L-Theanine increases intracellular GSH
DETAILED DESCRIPTION OF THE INVENTION
Definitions
All percentages are by weight of the total weight of the composition unless expressed otherwise. Similarly, all amounts and all ratios are by weight unless expressed otherwise. When reference is made to the pH, values correspond to pH measured at 25 °C with standard equipment. As used herein, “about,” “approximately” and “substantially” are understood to refer to numbers in a range of numerals, for example the range of -10% to +10% of the referenced number, preferably -5% to +5% of the referenced number, more preferably -1% to +1% of the referenced number, most preferably -0.1% to +0.1% of the referenced number.
Furthermore, all numerical ranges herein should be understood to include all integers, whole or fractions, within the range. Moreover, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 1 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
As used herein and in the appended claims, the singular form of a word includes the plural, unless the context clearly dictates otherwise. Thus, the references “a,” “an” and “the” are generally inclusive of the plurals of the respective terms.
Similarly, the words “comprise,” “comprises,” and “comprising” are to be interpreted inclusively rather than exclusively. Likewise, the terms “include,” “including” and “or” should all be construed to be inclusive, unless such a construction is clearly prohibited from the context. However, the embodiments provided by the present disclosure may lack any element that is not specifically disclosed herein. Thus, a disclosure of an embodiment defined using the term “comprising” is also a disclosure of embodiments “consisting essentially of’ and “consisting of’ the disclosed components.
Where used herein, the term “example,” particularly when followed by a listing of terms, is merely exemplary and illustrative, and should not be deemed to be exclusive or comprehensive. Any embodiment disclosed herein can be combined with any other embodiment disclosed herein unless explicitly indicated otherwise.
The “subject” or “individual” of the present invention is a human adult subject, preferably a healthy adult with the need to improve motivational performance through modulating glutathione levels in the brain. The compositions of the invention may be beneficially used for increasing glutathione level in the brain, in particular, the nucleus accumbens for preventing or treating conditions or diseases which are characterized by low glutathione levels in the brain, whether transient or chronic.
In biology and psychology, the term "stress" refers to the consequence of the failure of a human or other animal to respond appropriately to physiological, emotional, or physical threats, whether actual or imagined. The psychobiological features of stress may present as manifestations of oxidative stress, i.e., an imbalance between the production and manifestation of reactive oxygen species and the ability of a biological system readily to detoxify the reactive intermediates or to repair the resulting damage. Disturbances in the normal redox state of tissues can cause toxic effects through the production of peroxides and free radicals that damage all of the components of the cell, including proteins, lipids, and DNA. Some reactive oxidative species can even act as messengers through a phenomenon called "redox signaling."
“Reactive oxygen species” play important roles in cell signaling, a process termed redox signaling. Thus, to maintain proper cellular homeostasis a balance must be struck between reactive oxygen production and consumption. One source of reactive oxygen under normal
conditions in humans is the leakage of activated oxygen from mitochondria during oxidative phosphorylation. Other enzymes capable of producing superoxide (02-) are xanthine oxidase, NADPH oxidases and cytochromes P450. Hydrogen peroxide, another strong oxidizing agent, is produced by a wide variety of enzymes including several oxidases.
The terms “treatment” and “treating” include any effect that results in the improvement of the condition or disorder, for example lessening, reducing, modulating, or eliminating the condition or disorder. The term does not necessarily imply that a subject is treated until total recovery. Non-limiting examples of “treating” or “treatment of’ a condition or disorder include: (1) inhibiting the condition or disorder, i.e., arresting the development of the condition or disorder or its clinical symptoms and (2) relieving the condition or disorder, i.e., causing the temporary or permanent regression of the condition or disorder or its clinical symptoms. A treatment can be patient- or doctor-related.
The terms “prevention” or “preventing” mean causing the clinical symptoms of the referenced condition or disorder to not develop in an individual that may be exposed or predisposed to the condition or disorder but does not yet experience or display symptoms of the condition or disorder. The terms “condition” and “disorder” mean any disease, condition, symptom, or indication.
The relative terms “improved,” “increased,” “enhanced” and the like refer to the effects of the composition on increasing glutathione in the brain, in particular in the nucleus accumbens region of the brain, and subsequently improving the cognitive or motor performance in the individual subject.
“Motivational performance” is synonymous with the terms “mental energy” and related terms of “volition”, “will-power”, “time-on-task”, “persistence”, “focus”, “self-control”, “sustained effort”, “vigor” and “self-efficacy”. All these terms relate to a person’s drive to initiate and do things. Motivational performance is linked to subjectively perceived self-efficacy and well-being.
Motivational performance describes the subjective perception of mental resources available, which in turn is linked to cognitive functioning (Egan et al. (2015) Personality & Social Psychology Bulletin, 41(3), 336-350). For example, motivational performance is reduced in states of depression and anxiety (O’Connor et al. (2006) Nutrition Reviews, 64(7 Pt 2), S2-6).
Measurement of “motivational performance” can be by both motor tasks and cognitive tasks. Typically, these motor tasks and cognitive tasks are performed under incentivized conditions, meaning that individuals get an incentive depending on their performance of the task.
For example, a motor task under incentivized conditions may be measured as an individual’s ability to perform a strenuous motor task, e.g. squeezing a handgrip measuring both force and endurance wherein the performance is normalised for individual muscular strength (Zhu et al. (2019) Neuroimage. Clinical, 23, 101922).
For example, a cognitive task under incentivized conditions may be an individual’s ability to perform a strenuous cognitive task, e.g. continuous/sustained attention and working memory (e.g. Unsworth et al. (2019) Journal of Experimental Psychology. Learning, Memory, and Cognition), mental arithmetic, or spatial reasoning (e.g. Nagase et al. (2015) Journal of the Society for Neuroscience, 38(10), 2631-2651) wherein the performance is normalised for individual capacity to perform this task.
In animals, such as rodents, measurement of “motivational performance” is measured through motor tasks such as the forced swim test or cognitive tasks such as social dominance test or operant conditioning. Motivational performance can also be measured in relation to anxiety in tests such as “elevated plus maze” (e.g. Hollis et al. (2018) Neuropharmacology, 138, 245-256) and “open field and novel object” (e.g. Toledo-Rodgriguez and Sandi, (2011) Frontiers in Behavioral Neuroscience, 5, 17).
The “nucleus accumbens” is the most ventral part of the striatum and is mainly connected to the limbic system. As a functionally central structure between amygdala, basal ganglia, mesolimbic dopaminergic regions, mediodorsal thalamus and prefrontal cortex, the nucleus accumbens appears to play a modulative role in the flow of the information from the amygdaloid complex to these regions. Together with the prefrontal cortex and amygdala, nucleus accumbens consists a part of the cerebral circuit which regulates functions associated with effort or motivated performance. It is anatomically located in a unique way to serve emotional and behavioral components of feelings. It is considered as a neural interface between motivation and action, having a key-role in food intake, sexual behavior, reward-motivated behavior, stress-related behavior and substance-dependence (Mavridis, Psychiatriki. 2015 Oct-Dec;25(4):282-94). The present invention has surprisingly found that a higher level of glutathione measured in the nucleus accumbens significantly correlates with improved motivational performance (Figure 1)
while stress as measured by cortisol levels is negatively correlated with levels of glutathione in the nucleus accumbens.
The terms “food,” “beverage”, “food product”, “beverage product”, “food composition” and “beverage composition” mean a product or composition that is intended for ingestion by an individual such as a human and provides at least one nutrient to the individual. The compositions of the present disclosure, including the many embodiments described herein, can comprise, consist of, or consist essentially of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in a diet.
The composition can be any kind of composition that is suitable for human and/or animal consumption. For example, the composition may be selected from the group consisting of: food compositions, dietary supplements, nutritional compositions, nutraceuticals, powdered nutritional products to be reconstituted in water or milk before consumption, food additives, medicaments, beverages and drinks, including coffee based products (coffee RTD, coffee capsules, etc..). In an embodiment, the composition is an oral nutritional supplement (ONS), a complete nutritional formula, a pharmaceutical, a medical or a food product. In a preferred embodiment, the composition is administered to the individual as a beverage. The composition may be stored in a sachet as a powder and then suspended in a liquid such as water for use.
As used herein, “complete nutrition” contains sufficient types and levels of macronutrients (protein, fats and carbohydrates) and micronutrients to be sufficient to be a sole source of nutrition for the individual to which the composition is administered. Individuals can receive 100% of their nutritional requirements from such complete nutritional compositions.
Administration of the compositions of the invention encompass “enteral administration” in all forms, although of oral administration is preferred.
Each of the compounds can be administered at the same time as the other compounds (i.e., as a single unit) or separated by a time interval (i.e., in separate units).
All modes of administration may be considered in combination with glutathione per se.
“Functional derivatives” of compounds of the invention are derived from a similar compound by a chemical reaction. “Functional derivatives” can be formed from the same precursor compound and may be administered to increase glutathione levels in the brain.
A “kit” means that the components of the kit are physically associated in or with one or more containers and considered a unit for manufacture, distribution, sale, or use. Containers include, but are not limited to, bags, boxes, cartons, bottles, packages of any type or design or material, over-wrap, shrink-wrap, affixed components (e.g., stapled, adhered, or the like), or combinations thereof.
Embodiments
In several embodiments of the invention, a composition comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L-theanine or their functional derivatives and at least one B Vitamin.
The composition is for use in increasing glutathione levels in the brain and/or increasing motivational performance or mental energy and vigor in an individual. Such composition increases glutathione in the nucleus accumbens region of the brain to provide the benefits to the subject.
In a further embodiment, the B Vitamins comprises at least one of pyridoxine and/or Vitamin B12.
In a preferred embodiment, a composition of the invention is administered orally.
In a preferred embodiment, a composition is a food supplement or dietary supplement.
In a preferred embodiment, a composition is in the form of a tablet, a gummy or a powder sachet, for example.
In a preferred embodiment, a composition of the invention is in the form of an effervescent tablet.
In several embodiments of the invention, the composition is provided as a kit with a Digital tool, such as a companion App.
In several embodiments of the invention, a composition of the invention is used by healthy individuals in need of i) increasing motivational performance and/or mental energy, ii) increasing cognitive performance, iii) increasing productivity.
In several embodiments of the invention, a composition of the invention is used in decreasing performance anxiety and/or stress.
Glutathione
Glutathione (GSH) is the most abundant intracellular component of overall antioxidant defenses. GSH, a tripeptide, is synthesized from precursor amino-acids: glycine, cysteine and glutamate in two steps catalyzed by glutamate cysteine ligase (GCL, also known as gamma-glutamylcysteine synthetase, EC 6.3.2.2) and gamma-L-glutamyl-L-cysteine:glycine ligase (also known as glutathione synthetase, EC 6.3.2.3), and GSH synthesis occurs de novo in cells.
Glutathione is also known as Gamma-Glutamylcysteinylglycine, Gamma-L-Glutamyl-L- Cysteinylglycine, Gamma-L-Glutamyl-L-Cysteinylglycine, Glutathion, Glutation, L-Gamma- Glutamyl-L-Cysteinyl-Glycine, L-Gamma-Glutamyl-L-Cysteinyl-Glycine, L-Glutathion, L- Glutathione, GSH, N-(N-L-gamma-Glutamyl-L-cysteinyl)glycine. It is typically administered as S- acetyl glutathione or reduced L-glutathione.
Glutathione-rich food include: cruciferous vegetables, for example, broccoli, cauliflower,
Brussels sprouts, and bok choy; allium vegetables, for example, garlic and onions; eggs, nuts, legumes, lean protein, such as fish, and chicken as well as whey protein. Glutathione-rich herbs include: for example, milk thistle, flaxseed, guso seaweed. Compositions and methods of the invention can also be used in combination with dietary recommendations for a glutathione-rich food to complement the diet.
Lifestyle parameters may affect levels of glutathione in the brain. For example, glutathione is also negatively affected by insomnia. Therefore, compositions and methods of the invention would also include the recommendation to have sufficient sleep.
Psychogenic stress is defined as a state of imminent or perceived threat to homeostasis, where the brain and body invoke various physiological responses to adapt. Glutathione levels in the brain may be affected by such stress.
Glycine
Glycine or functional derivative thereof is selected from the group consisting of L-glycine, L- glycine ethyl ester, D-Allylglycine; N-[Bis(methylthio)methylene]glycine methyl ester; Boc-allyl- Gly-OH (dicyclohexylammonium) salt; Boc-D-Chg-OH; Boc-Chg-OH; (R)-N-Boc-(2'- chlorophenyl)glycine; Boc-L-cyclopropylglycine; Boc-L-cyclopropylglycine; (R)-N-Boc-4- fluorophenylglycine; Boc-D-propargylglycine; Boc-(S)-3-thienylglycine; Boc-(R)-3-thienylglycine; D-a-Cyclohexylglycine; L-a-Cyclopropylglycine; N-(2-fluorophenyl)-N-(methylsulfonyl)glycine; N- (4-fluorophenyl)-N-(methylsulfonyl)glycine; Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH; N-(2-
Furoyl)glycine; L-a-Neopentylglycine; D-Propargylglycine; sarcosine; Z-a-Phosphonoglycine trimethyl ester, and mixtures thereof.
The glycine or functional derivative thereof can be administered in an amount of about 0.1 - 100 milligram (mg) of glycine or functional derivative thereof per kilogram (kg) of body weight of the subject.
In a particular non-limiting example, the daily doses for a 60 kg subject can be 6 to 6,000 mg/day for glycine or a functional derivative thereof.
Ergothioneine
Ergothioneine is also known as ergothionine, 1-carboxy-2-[2-mercaptoimidazole-4-(or 5)- yljethylj-trimethyl-ammonium hydroxide, 2-Mercaptohistidine Trimethylbetaine, or I- ergothioneine. It is an amino acid that is found mainly in mushrooms, but also in king crab, meat from animals that have grazed on grasses containing ergothioneine, and other foods.
In a particular non-limiting example, the daily dosing of ergothioneine or a functional derivative thereof may be administered at 2 to 25 mg/day.
L-theanine
L-theanine is synthesized from glutamic acid and ethylamide and found in foods such as green tea. It is not an antioxidant itself but promotes glutathione.
In a particular non-limiting example, the daily dosing of l-theanine or a functional derivative thereof may be administered at 50 mg to 200 mg/day.
Sulforaphane
Sulforaphane exists in food in its food-bound form known as Glucoraphanin, a glycoside (bound to a sugar) or sulforaphane that is commonly seen as a prodrug or storage form of Sulforaphane.
In a particular non-limiting example, the daily dose of sulforaphane or a functional derivative thereof may be administered at 7 to 57 mg/day.
Whey proteins
Whey proteins and whey protein isolates contain high amounts of amino acids such as glycine, cysteine and leucine, especially in isolates enriched for alpha-lac.
In a particular non-limiting example, the daily dose of whey protein is 0.8 to 2.5g/kg body weight of whey proteins per day.
Taurine
Taurine also known as 2-aminoethanesulfonic acid is an organic acid that occurs naturally in food, especially in shellfish (eg, scallops, mussels, clams) and in the dark meat of turkey and chicken, as well as in other meats and eggs.
In a particular non-limiting example, the daily doses for a 60 kg subject up to 3000 mg/day of taurine or a functional derivative thereof.
B Vitamins
One or more B vitamins are used in the composition. Non-limiting examples of suitable B vitamins include Vitamin B1 (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (niacin or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements)and combinations thereof. “Vitamin” includes such compounds obtained naturally from plant and animal foods or synthetically made, pro-vitamins, derivatives thereof, and analogs thereof.
Pyridoxine
Pyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods.
In an embodiment, vitamin B6 can include one or more of the following: pyridoxine (PN), pyridoxal 5'-phosphate (PLP), pyridoxine 5'-phosphate (P5P), pyridoxal (PL), pyridoxamine (PM), pyridoxamine 5'-phosphate (PMP), 4-pyridoxic acid, and pyritinol. In a preferred embodiment, at least a portion of any vitamin B6 is PN. At least a portion of the vitamin B6 can be PLP. Absorbed pyridoxamine is converted to PMP by pyridoxal kinase, which is further converted to PLP by pyridoxamine-phosphate transaminase or pyridoxine 5'-phosphate oxidase which also catalyzes the conversion of PNP to PLP. [2] Pyridoxine 5'-phosphate oxidase is dependent on flavin mononucleotide (FMN) as a cofactor produced from riboflavin (vitamin B2).
In an embodiment, Vitamin B6 can be administered in an amount of vitamin B6 in a daily dosage of about 1.0-600 mg vitamin B6, for example about 1.0-200mg vitamin B6, for example about 1.0-25.0 mg vitamin B6, for example about 10-20mg of Vitamin B6 / day.
A daily dose of the composition can provide 0.1 to 50 times the recommended daily requirement (RDA) of Vitamin B12 per day, more preferably 0.1 to 40 times the recommended daily requirement (RDA) of Vitamin B12 Such dosages may preferably include a daily dose of about 10, 20, 30, or 40 times the RDA of the Vitamin B12 per day. Preferably, the daily dose provides 10 to 40, more preferably 10 to 30 or even more preferably 10 to 25 times the RDA of the Vitamin B12 per day, most preferably about 12 to 21 times the RDA of the Vitamin B12 per day. Further in this regard, the United States RDA of Vitamin B12 is 2.4 micrograms daily for humans of age 14 years and older, so such individuals may be administered a daily dose of the composition that provides about 0.002 mg to about 0.4 mg of Vitamin B12 per day, preferably 0.02 to 0.07 mg of Vitamin B12 per day, more preferably 0.03 to 0.05 mg of Vitamin B12 per day.
One or more other vitamins are used in the composition. Non-limiting examples of suitable other vitamins include vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin K, folic acid and biotin), and combinations thereof. “Vitamin” includes such compounds obtained naturally from plant and animal foods or synthetically made, pro-vitamins, derivatives thereof, and analogs thereof.
Composition formulations
In one embodiment, the compositions are food compositions, including human and pet food compositions. In several embodiments, the food composition is a product with at least one nutrient for improving motivation performance or mental energy/ vigor.
For pet food compositions, they may supply the necessary dietary requirements for an animal, animal treats (e.g., biscuits), or dietary supplements. The compositions may be a dry composition (e.g., kibble), semi-moist composition, wet composition, or any mixture thereof. In another embodiment, the composition is a dietary supplement such as a gravy, drinking water, beverage, yogurt, powder, granule, paste, suspension, chew, morsel, treat, snack, pellet, pill, capsule, tablet, or any other suitable delivery form. The dietary supplement is to be administered to the animal in small amounts, or in the alternative, can be diluted before administration to an animal. The dietary supplement may require admixing or can be admixed with water or other diluent prior to administration to the animal.
In another embodiment, the composition is in the form of a food supplement or dietary supplement, in particular in the form of a tablet, a powder sachet or a gummy.
In a preferred embodiment, the composition is in the form of an effervescent tablet.
The effervescent tablets can be produced and controlled same as conventional tablets. These controls include physicochemical properties such as hardness, weight variation, friability, solution time, pH and content uniformity. The effervescent tablets can be produced by a direct compression method, a fusion method, a wet or dry granulation method, or any other suitable method. Low relative humidity (e.g., maximum of 25% or less) and moderate to cool temperatures (e.g., about 25 °C or 77 °F) in the environment may be essential to prevent sticking granule or tablets to the tablet press machine.
In the direct compression method, the effervescent tablet can be formed by compressing the ingredients in the form of powders into a dense mass, for example, by a tablet press machine. The powdered ingredients may be first granulized to similar or equal sizes before being made into tablets, so that the mixtures of powder have excellent flowability without particles segregation. Granulating may not be required if the raw materials are selected to achieve a free- flowing, non-segregating, compressible powder blend. The tablets can then be dried by heat, such as in an oven with air circulation, at a suitable temperature for a suitable time and after cooling can be packed in a suitable package.
In the fusion method, the ingredients can be mixed in a suitable mixer, such as a blender, for an appropriate time. Then, the obtained mixture can be heated to a suitable temperature. The powder may be mixed regularly until the crystallization water of citric acid is released as binder factor (e.g., approximately 30 minutes) and an appropriate pasty mass is obtained. This wet mass can be passed through a sieve to obtain the desired granules, which can then be dried at a suitable temperature for an appropriate time. After drying, the granules can be passed through the sieve again. Other ingredients can be added to the granule mass and mixed for a suitable time. The granule mixtures then can be compressed into tablets by the tablet press machine. Finally, the tablets can be dried and packed in a suitable package.
In the wet granulation method, the ingredients may be milled by a miller, either separately or as a mixture with ethanol, ethanol-water mixture, isopropanol, etc., and the obtained powder can be passed through a sieve and then blended. A binder solution can be added to the mixture to form a pasty mass. This pasty mass can then be passed through a sieve to obtain desired granules, which can then dried. The dried mass can be passed through a sieve again, and
other ingredients can be added and mixed. The obtained granule mixtures then can be compressed into tablets by the tablet press machine. Finally, the tablets can be dried and packed in a suitable package. Wet granulation can also be performed by carefully adding 0.1 to 1.0 per cent water (weight-to-weight basis) to a blend of raw materials that possess the uniformity, compressibility, and flowability needed to produce good-quality tablets, but which lacks the needed binding properties. The free water which is usually added in the form of a fine spray to selected formulation components while mixing in a suitable blender acts as a binder. The granulation steps must be precisely timed and the ingredients mixed thoroughly to distribute the granulating fluid evenly in the blend. The mix is then quickly discharged to drying ovens. After drying, the granules are sized, and a final mix is performed. The granules are then compressed into tablets using tablet machines.
The dry granulation method can use special processing equipment known as a “roller compactor” or “chilsonator.” These machines compress premixed powders between two counterrotating rollers under extreme pressure. Depending on the configuration of the roller, the feed material may be compacted into dense ribbon-like materials known as flakes (smooth rolls) or dense briquettes (almond or stick-shaped) if the rollers have grooved or etched surfaces.
The compressed material is reduced to the proper size for tablet granulation purposes. Another dry granulation procedure is slugging, in which the powder particles are compressed into large flat tablets or pellets using a tablet press or more usually, a heavy-duty tablet-compacting equipment. The resulting tablet or slug are milled to yield the desired granule characteristics.
The effervescent tablet can be made in any shape and can have any suitable size. As non limiting examples, the tablet can be 5 mm to 20 mm long, thick, and/or in diameter if having a round shape. The size of the tablet can be from 5 mm to 10 mm, 5 mm to 15 mm, 10 mm to 15 mm, 10 mm to 20 mm, or 15 mm to 20 mm.
The effervescent tablet may comprise a binder, such as polyvinylpyrolidone (PVP) or any other suitable binder. The binder is preferably water-soluble. It can be added as dry powder or in a wet form as an aqueous or hydroalcoholic solution. Mannitol, PEG 6000 and water in small amounts can also be used as a binder. PEG 6000 at 3% use level can be used as a dry binder. The ideal amount of binder is one that makes the tablet hard enough to handle but soft enough to disintegrate and dry enough to be stable. The effervescent tablet may also be formulated without a binder.
Beverage compositions
In one embodiment, the compositions are beverage compositions. Such beverage compositions are meant to be consumed by a human or animal. In several embodiments, the beverage is a milk-based beverage; a performance nutrition product, a medical nutrition product; a milk product, e.g. a milk drink, a product with at least one nutrient for improving motivation performance (incl. focus) or mental energy (incl. vigor).
Dairy product
In one embodiment, the composition can be formulated as a “dairy product” together with milk proteins, e.g., milk protein concentrate or milk protein isolate; caseinates or casein, e.g., micellar casein concentrate or micellar casein isolate; or whey protein, e.g., whey protein concentrate or whey protein isolate. Additionally, or alternatively, at least a portion of the protein can be plant protein such as one or more of soy protein, pea protein or canola protein.
Nutritional supplement
In one embodiment, the composition of the invention can be formulated as a “nutritional supplement” together with glutathione enhancing compounds of the invention. The compounds of the invention can be used alone or in combination with appropriate additives to make tablets, gummies, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose functional derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
Administration
The composition of the invention can be administered at least one day per week, preferably at least two days per week, more preferably at least three or four days per week (e.g., every other day), most preferably at least five days per week, six days per week, or seven days per week. The time period of administration can be at least one week, preferably at least one month, more preferably at least two months, most preferably at least three months, for example at least four months. In an embodiment, dosing is at least daily; for example, a subject may receive one or more doses daily. In some embodiments, the administration continues for the remaining life of the individual. In other embodiments, the administration occurs until no detectable symptoms of
the condition remain. In specific embodiments, the administration occurs until a detectable improvement of at least one symptom occurs and, in further cases, continues to remain ameliorated.
The ideal duration of the administration of the composition can be determined by those of skill in the art.
Digital Tool / Companion App
In a preferred embodiment, the composition is provided as a kit with a Companion App.
In some embodiments, the composition or kit helps the individual to achieve objectives and/or to support his motivation or focus; reduces his perception of effort to reach his objectives. Such objectives may include any global objectives or daily objectives related to pre-defined goals embodied within the app, such as lifestyle changes, including weight-loss, healthy eating, physical exercise or productivity at work or in private life, as well as any other user-defined goals.
In some embodiments, the companion app presents a onboarding questionnaire, displayed on first launch, to determine consumer wishes and concerns.
In some embodiments, the companion app tracks the progress towards the objectives, as well as activities (physical activity, sleep duration, etc..), optionally through digital tools (connected watch, etc).
In some embodiments, the companion app allows the user to indicate whether or not they have consumed the product.
In some embodiments, the companion app allows the user to capture their mood each day, and visualize the mood together with daily goals in a graph or timeline format.
In some embodiments, the companion app provides rewards in the form of digital trophies, kudo points, or discount vouchers.
Those skilled in the relevant art will appreciate which technology, logic and algorithm can be practiced to program, configure or construct the companion app or another equivalent digital tracking tool.
EXAMPLE
Example 1: Measurement of intracellular glutathione (GSH) in rat primary astrocyte culture
Intracellular GSH was measured in rat primary astrocytes in culture by using a GSH-Glo™ Assay, which is a luminescent-based assay for the detection and quantification of reduced and/or total glutathione levels in cells. The assay converted luciferin derivatives into luciferin in the presence of GSH. The reaction was catalyzed by a glutathione S-transferase (GST) enzyme supplied in the kit. The luciferin formed was detected in a coupled reaction using Ultra-Glo™ Recombinant Luciferase that generated a glow type luminescence that was proportional to the amount of glutathione present in cells. A standard curve was used for each biological replicate and at least 4 technical replicates were done for each condition and for each biological replicate. 10% of lysate of each technical and biological replicate was used to measure protein amount by BCA and used to normalize the GSH intracellular content to total proteins. Buthionine sulfoximine (BSO) a specific inhibitor of g-glutamylcysteine ligase (GCL) was added at 15mM at the time of the start of the treatment to confirm the specificity of the readout. Measurements were performed 48hrs after treatment. Results were compared to the control condition for each biological replicate and for each condition.
Figure 1 demonstrates that Sulfurophane increases intracellular glutathione.
Figure 2 demonstrates that Taurine increases intracellular glutathione.
Figure 3 demonstrates that Ergothioneine increases intracellular glutathione.
Figure 4 demonstrates that L-theanine increases intracellular glutathione.
This demonstrate that the various different compounds of the invention have different complementary mechanisms of action which surprisingly work together to increase glutathione.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims
1. Composition comprising at least one compound selected from glycine, taurine, whey protein, sulforaphane, ergothioneine and L-theanine or their functional derivatives and at least one B vitamin.
2. Composition according to claims 1 , for use in increasing glutathione levels in the brain and/or increasing motivational performance or mental energy in an individual.
3. Composition according to claims 1 or 2 wherein the B Vitamin comprises at least one of pyridoxine, Vitamin B9 and/or Vitamin B12.
4. Composition according to any one of preceding claims, wherein said composition is administered orally.
5. Composition according to any one of preceding claims, wherein said composition is a food supplement or dietary supplement.
6. Composition according to any of preceding claims, wherein the composition is in the form of a beverage, an RTD, an RTD coffee, a coffee capsule, a tablet, a gummy or powder sachet.
7. A Composition according to any one of claims 1 to 6, provided as a kit together with a digital tool, such as a companion App.
8. Composition according to any of claims 1 to 7, wherein the composition or kit helps the individual to achieve his objectives and/or to support his motivation; reduces his perception of effort to reach his objectives.
9. Use of the composition of any one of claims 1 to 8 in healthy individuals in need of at least one of i) increasing motivational performance and/or mental energy; ii) increasing cognitive performance, and iii) increasing productivity.
10. Composition according to any one of claims 1 to 9 for use in decreasing performance anxiety and/ or stress.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21175144 | 2021-05-21 | ||
EP21175144.1 | 2021-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022243510A1 true WO2022243510A1 (en) | 2022-11-24 |
Family
ID=76059665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/063711 WO2022243510A1 (en) | 2021-05-21 | 2022-05-20 | Combinations for use in brain health and increasing motivation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022243510A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213401A1 (en) * | 2007-02-07 | 2008-09-04 | Smith Kyl L | Nutritional supplements for healthy memory and mental function |
US20120141611A1 (en) * | 2010-12-05 | 2012-06-07 | Oxis International Inc. | Methods and compositions using ergothioneine to treat a variety of health related factors |
US20140170211A1 (en) * | 2012-12-18 | 2014-06-19 | Matthew Bennett | Compositions and methods for treating traumatic brain injury |
WO2019005962A1 (en) * | 2017-06-27 | 2019-01-03 | Harmonix, Llc | Time release sleep aid system |
-
2022
- 2022-05-20 WO PCT/EP2022/063711 patent/WO2022243510A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213401A1 (en) * | 2007-02-07 | 2008-09-04 | Smith Kyl L | Nutritional supplements for healthy memory and mental function |
US20120141611A1 (en) * | 2010-12-05 | 2012-06-07 | Oxis International Inc. | Methods and compositions using ergothioneine to treat a variety of health related factors |
US20140170211A1 (en) * | 2012-12-18 | 2014-06-19 | Matthew Bennett | Compositions and methods for treating traumatic brain injury |
WO2019005962A1 (en) * | 2017-06-27 | 2019-01-03 | Harmonix, Llc | Time release sleep aid system |
Non-Patent Citations (11)
Title |
---|
EGAN ET AL., PERSONALITY & SOCIAL PSYCHOLOGY BULLETIN, vol. 41, no. 3, 2015, pages 336 - 350 |
HOLLIS ET AL., NEUROPHARMACOLOGY, vol. 138, 2018, pages 245 - 256 |
MAVRIDIS, PSYCHIATRIKI, vol. 25, no. 4, October 2015 (2015-10-01), pages 282 - 94 |
NAGASE ET AL., JOURNAL OF THE SOCIETY FOR NEUROSCIENCE, vol. 38, no. 10, 2015, pages 2631 - 2651 |
O'CONNOR ET AL., NUTRITION REVIEWS, vol. 64, 2006, pages S2 - 6 |
T.-Y. SONG ET AL: "Ergothioneine and melatonin attenuate oxidative stress and protect against learning and memory deficits in C57BL/6J mice treated with D-galactose", FREE RADICAL RESEARCH, vol. 48, no. 9, 12 September 2014 (2014-09-12), GB, pages 1049 - 1060, XP055712620, ISSN: 1071-5762, DOI: 10.3109/10715762.2014.920954 * |
TOLEDO-RODGRIGUEZSANDI, FRONTIERS IN BEHAVIORAL NEUROSCIENCE, vol. 5, 2011, pages 17 |
UNSWORTH ET AL., JOURNAL OF EXPERIMENTAL PSYCHOLOGY. LEARNING, MEMORY, AND COGNITION, 2019 |
ZALACHORAS IOANNIS ET AL: "Therapeutic potential of glutathione-enhancers in stress-related psychopathologies", NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, PERGAMON PRESS LTD, AMSTERDAM, NL, vol. 114, 18 May 2020 (2020-05-18), pages 134 - 155, XP086171300, ISSN: 0149-7634, [retrieved on 20200518], DOI: 10.1016/J.NEUBIOREV.2020.03.015 * |
ZHU, NEUROLMAGE. CLINICAL, vol. 23, 2019, pages 101922 |
ZUHAL YILDIRIM ET AL: "Effects of Taurine and Age on Cerebellum Antioxidant Status and Oxidative Stress", INTERNATIONAL JOURNAL OF GERONTOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 5, no. 3, 12 August 2010 (2010-08-12), pages 166 - 170, XP028346252, ISSN: 1873-9598, [retrieved on 20110930], DOI: 10.1016/J.IJGE.2011.09.019 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2703693C (en) | Anti-fatigue agent comprising amino acid composition | |
Brestenský et al. | Branched chain amino acids and their importance in nutrition | |
KR101528381B1 (en) | Composition comprising sesamin component and vitamin b1 component | |
WO2020092451A1 (en) | Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans | |
EP3968973A1 (en) | Compositions and methods using a combination of calcium and at least one of oleuropein or metabolite thereof | |
US11172692B2 (en) | Horse supplement | |
KR20180029963A (en) | Amino acid supplement | |
CA3140735A1 (en) | Compositions and methods using trigonelline and vitamins for preventing or treating conditions or disorders in skeletal muscle | |
TW202135801A (en) | Composition containing sesamin and PQQ | |
JP2017057147A (en) | Composition comprising garlic and the like, low-salinity miso, and vitamin b1 | |
JP2007031309A (en) | Anti-stress composition | |
KR20110117685A (en) | A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
WO2022243510A1 (en) | Combinations for use in brain health and increasing motivation | |
EP3634396B1 (en) | Composition for improving efficacy of l-dopa treatment | |
WO2022162036A1 (en) | Compositions and methods for use in increasing motivational performance | |
WO2024105221A1 (en) | Combination for use in brain health and increasing mental performance | |
JP2005082495A (en) | Cerebral cell-protecting composition | |
AU2020310493A1 (en) | Compositions and methods using trigonelline and high protein for preventing or treating conditions or disorders in skeletal muscle | |
WO2020210540A2 (en) | Nutrient compositions and methods for administering a nutrient composition | |
JP4131443B2 (en) | Anti-osteoporosis composition | |
US20230346818A1 (en) | Compositions and methods containing n-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions | |
Nørby et al. | Assessment of added amino acids to foods and food supplements | |
CA3140733A1 (en) | Compositions and methods using trigonelline and minerals for preventing or treating conditions or disorders in skeletal muscle | |
CN115154516A (en) | Composition for improving appetite and/or promoting digestive absorption and application thereof | |
Naeem et al. | All About Vitamins and Its Role in Oral Health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22729695 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22729695 Country of ref document: EP Kind code of ref document: A1 |